Adage Capital Partners Gp, L.L.C. Amylyx Pharmaceuticals, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$18.08 - $23.45 $16.9 Million - $21.9 Million	932,000 Added 121.32%	1,700,200 $31.1 Million
Q2 2023 Aug 14, 2023	SELL	$20.98 - $31.42 $5.02 Million - $7.51 Million	-239,136 Reduced 23.74%	768,200 $16.6 Million
Q1 2023 May 15, 2023	SELL	$27.71 - $40.93 $25 Million - $36.9 Million	-901,865 Reduced 47.24%	1,007,336 $29.6 Million
Q4 2022 Feb 14, 2023	BUY	$29.75 - $39.26 $16.6 Million - $22 Million	559,201 Added 41.42%	1,909,201 $70.5 Million
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $19.7 Million - $35.6 Million	1,150,000 Added 575.0%	1,350,000 $38 Million
Q2 2022 Aug 15, 2022	BUY	$6.85 - $19.93 $1.12 Million - $3.24 Million	162,800 Added 437.63%	200,000 $3.85 Million
Q1 2022 May 16, 2022	BUY	$12.85 - $32.9 $478,020 - $1.22 Million	37,200 New	37,200 $478,000

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $308M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.